Table 3. Hematological toxicity and peripheral neuropathy with rescue protocols.
| Adverse events (AEs) | Anemia | Neutropenia | Thrombocytopenia | Peripheral neuropathy | Second primary neoplasm | ||||
|---|---|---|---|---|---|---|---|---|---|
| Toxicity | All | G3/4 | All | G3/4 | All | G3/4 | G0-5 (%) | ≥ G3 (%) | — |
| POLLUX daratumumab arm* [11, 12, 23, 25] | 37 | 16 | 61 | 54 | 29 | 14 | NR | NR | 5.7 |
| ASPIRE carfilzomib arm# [26–30] | 43 | 19 | 40 | 31 | 29 | 17 | 19 | 3 | NR |
| ELOQUENT 2 elotuzumab arm& [13, 14, 31] | 97 | 20 | 83 | 36 | 84 | 21 | NR | NR | * |
| TOURMALINE-MM 1 ixazomib arm# [15] | 29 | 9 | 33 | 23 | 31 | 19 | 27 | 2 | 5 |
| CASTOR daratumumab arm* [11, 16–18] | 26 | 14 | 18 | 13 | 59 | 45 | 50 | 5 | 4.1 |
| ENDEAVOR carfilzomib arm## [19, 20, 30] | 40 | 15 | NR | NR | 21 | 9 | 10 | 1 | NR |
| OPTIMISMM pomalidomide arm [21] | 28 | 13.7 | 46.8 | 82.1 | 36.7 | 27.3 | 47.8 | 8.3 | 3 |
| PANORAMA1 panobinostat arm [22] | 62 | 18 | 75 | 35 | 98 | 68 | 61 | 18 | NR |
| Lenalidomide, dexamethasone (POLLUX) [11, 12, 17, 25] | 39* | 21 | 45 | 40 | 31 | 16 | 17–22 | 3 | 3.6–5.7 |
| Lenalidomide, dexamethasone (ASPIRE) [26–30] | 40# | 18 | 35 | 28 | 24 | 13 | |||
| Lenalidomide, dexamethasone (ELOQUENT-2) [13, 14, 31] | 95& | 21 | 89 | 45 | 78 | 21 | |||
| Lenalidomide, dexamethasone (TOURMALINE-MM1) [15] | 27## | 13 | 31 | 24 | 16 | 9 | |||
| Bortezomib, dexamethasone (Castor) [11, 16–18] | 31* | 16 | 9 | 4 | 44 | 33 | 29–38 | 7 | 1 |
| Bortezomib, dexamethasone (ENDEAVOR) [19, 20, 30] | 28## | 11 | NR | NR | 17 | 9 | 29 | 6 | NR |
| Bortezomib, dexamethasone (OPTIMISMM) [21] | 27 | 14 | 11 | 9 | 38 | 29 | 37 | 4 | 1 |
| Bortezomib, dexamethasone (PANORAMA1) [22] | 52 | 19 | 48 | 8 | 84 | 31 | 67 | 15 | |
* All degrees (≥ 15%) and degree 3/4 (≥ 5%); #(≥ 20%); &(≥ 30%); ##≥ 10% and degree 3/4/5 ≥ 2%.